| Amount : | 5 mg |
| Purification : | ≥98% |
| Content : | Boceprevir is supplied as a crystalline solid. |
| Storage condition : | Store at -20°C, product is stable for at least two years. |
| Alternative Name : | SCH 503034, Victrelis, |
Molecular Formula:C27H45N5O5,
Molecular Weight:519.7
Boceprevir is a protease inhibitor that covalently, yet reversibly, binds (Ki = 14 nM) to the catalytic site (Ser139) of hepatitis C virus (HCV) nonstructural protein 3/4A (NS3/4A), a serine protease that is essential for viral replication.It was shown to inhibit the NS3/4A protease in an in vitro HCV replicon system with an EC50 value of 200 nM.1 Boceprevir can inhibit the activity of recombinant HCV genotype 1a and 1b NS3/4A protease enzymes in vitro with Ki values of 14 nM for each subtype.2 It has been evaluated in phase III clinical studies in combination with the current standard of care for treatment of HCV.
For Research Use Only. Not for use in diagnostic/therapeutics procedures.
There are currently no product reviews Write a review on this product! |
Customers who purchased this product also purchased
BCMA Blocking Peptide


Langerin Stable Cell Line


mB7-H4 Stable Cell Line


hB7-H4 Stable Cell Line


CTLA4 Stable Cell Line


CD80 Stable Cell Line


ICOSL Stable Cell Line


ICOS Stable Cell Line


PD-L2 Stable Cell Line


PD-L1 Stable Cell Line


PD-1 Stable Cell Line


GATA3 Leeporter™ Luciferase ...


TNF-beta Leeporter™ Lucifera...


TNF-beta Leeporter™ Lucifera...

BCMA Blocking Peptide


Langerin Stable Cell Line


mB7-H4 Stable Cell Line


hB7-H4 Stable Cell Line


CTLA4 Stable Cell Line


CD80 Stable Cell Line


ICOSL Stable Cell Line


ICOS Stable Cell Line


PD-L2 Stable Cell Line


PD-L1 Stable Cell Line


PD-1 Stable Cell Line


GATA3 Leeporter™ Luciferase ...


TNF-beta Leeporter™ Lucifera...


TNF-beta Leeporter™ Lucifera...

Most viewed Products

Recombinant Human Thioredoxin-Like ...


Monoclonal antibody to Human PD-L1 ...


Monoclonal Antibody to Human IL-1be...


Monoclonal Antibody to Caspase-3 (P...


Polyclonal Antibody to Beta actin


Monoclonal Antibody to GAPDH (Clone...


Monoclonal antibody to B7-H4 (Clone...


Polyclonal Antibody to Beta Tubulin


NF-kB Leeporter™ Luciferase Repor...


Peroxidase conjugated Goat anti Mou...

ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
认领翻译的战友请跟帖注明“认领本文翻译,48小时内未完成,请其他站友认领”
MaggotsFasterThanScalpelinWoundDebridement
December19,2011—Maggotdebridementtherapy(MDT)appearstobemoreeffectiveforwounddebridementcomparedwithconventionaltherapy,butonlyat1week;afterthattime,anothertypeofdressingshouldbeused,newresearchsuggests.
KristinaOpletalovà,MD,fromtheDepartmentofDermatology,UniversityofCaen,France,andcolleaguespublishedonlineDecember19intheArchivesofDermatology.
MedicalmaggotswereapprovedbytheUSFoodandDrugAdmiNISTrationasamedicaldeviceforwounddebridementin2004.Accordingtotheresearchers,useofmaggotsintreatingwoundsisassociatedwitheffectivewounddebridement,antibacterialeffects,andstimulationofwoundhealing.
However,theypointout,"[r]elativelyfewclinicalstudieshavebeenconductedandtheresultsarenotclear,partlyowingtomethodologicassessmentproblems."
InthecurrentProspective,randomizedcontrolled,phase3clinicaltrial,theresearcherssoughttodeterminetheefficacyofbaggedlarvaeonwounddebridementincomparisonwithconventionaltreatment.
TheprimaryobjectivewastocomparethemeanpercentageofsloughinwoundstreatedwithMDTwiththatofconventionaltreatmentatday15.Thestudyincluded119patientswithanonhealing,sloughywoundthatwas40cm2orsmallerandlessthan2cmdeep.Patientsalsohadananklebrachialindexof0.8orhigher.
Treatmentwasadministeredduringa2-weekhospitalstay.Conventionaltreatmentconsistedofsurgicaldebridement3timesaweekwithascalpel,withuseoftopicalanesthesia.TheMDTwasadministeredusinganencloseddressing(Vitapad,BioMondeLaboratories)containing80sterilemaggots.Atdischarge,aconventionaldressingwasapplied,andpatientswerefollowed-upatday30.
DebridementbyMDTwassignificantlyfasterthansurgicaldebridementduringthefirstweekoftreatment,reachingthesamelevelthecontrolgroupreachedatday15.NobenefitforMDTcomparedwithconventionaltreatmentinhealingrateswasobserved.Atday8,54.5%intheMDTgroupvs66.5%inthecontrolgroup(P=.04)hadevidenceofsloughandwoundhealing.However,byday15,themeanpercentageofsloughwas55.4%intheMDTgroupand53.8%inthecontrolgroup(P=.78).
"AthoughMDTshowsnosignificantbenefitatday15comparedwithconventionaltreatment,debridementbyMDTissignificantlyfasterandoccursduringthefirstweekoftreatment,"theresearchersconclude."Becausethereisnobenefitincontinuingthetreatmentafter1week,anothertypeofdressingshouldbeusedafter2or3applicationsofMDT."
Painscoresweresimilarandmildinbothgroups,althoughincontrasttoconventionaltreatment,MDTwasperformedwithouttopicalanesthesia.
Accordingtotheresearchers,noneofthepatientswerereticentaboutundergoingMDT."[A]crawlingsensationonthewoundwasrarelyandalmostequallynotedinbothgroups,revealingthatthesensationwassubjective,"Dr.Opletalovàandcolleaguespointout.
TwoquestionsregardingMDTremainunanswered,theauthorsnote."Candebridementbeimprovedusingmoremaggotsperdressing?Ifso,wouldthesedressingsbemorepainful?Furtherstudiesareneededtoanswerthesequestions."
ThestudywassupportedbygrantsfromtheClinicalResearchHospitalProgramandfromtheFrenchSocietyofDermatology.Theauthorshavedisclosednorelevantfinancialrelationships.
2.微孔板:选择实验所需的板条数。剩余不用的部分随同干燥剂密封放回原袋。 1.包被有抗抑制素bB亚单位抗体的微孔板(Anti-InhibinB-CoatedMicrotitrationStrips):96孔,2-8ºC下密封保存。
2.标准品A/样本稀释液(InhibinBStandardA/SampleDiluent):2ml×1瓶,胎牛血清,含0pg/mL二聚体抑制素B。使用前2-8ºC下保存。打开后2-8ºC下可保存2周。于-20ºC可长期保存。
3.标准品B-G(InhibinBStandardsB-G):1ml×6瓶,胎牛血清,含二聚体抑制素B的浓度为10,30,100,250,500,1000pg/mL。使用前2-8ºC下保存。打开后2-8ºC下可保存2周。于-20ºC可长期保存。
4.质控(InhibinBControls):1ml×2瓶,浓度I、II,胎牛血清,含低浓度和高浓度的抑制素A二聚体。使用前2-8ºC下保存。打开后2-8ºC下可保存2周。于-20ºC可长期保存。
5.样本稀释液A(InhibinBSampleBufferA):10ml×1瓶,2-8ºC下保存。
6.样本稀释液B(InhibinBSampleBufferB):10ml×1瓶,2-8ºC下保存。
7.抗体-生物素结合物(InhibinBAntibody-BiotinConjugate)(即用型):10ml×1瓶,含生物素标记的抗抑制素a亚单位抗体。2-8ºC下保存。
8.酶结合物(浓缩)(Streptavidin-EnzymeConjugate)(即用型):10ml×1瓶,含链霉和素-辣根过氧化物酶结合物。2-8ºC下保存。
9.TMB底物溶液(TMBChromogenSolution):15ml×1瓶,2-8ºC下保存。
10.终止液(StoppingSolution):15ml×1瓶,为0.2M的硫酸。2-8ºC下保存。
11.浓缩洗液(WashConcentrate):100ml×1瓶,2-8ºC下保存。 操作前所有试剂都应平衡至室温(~25ºC)并充分混匀。标准品、质控及待测样本需同时做双份。
1.取出实验所需板条,并记录各孔位置。
2.在对应的孔中加入标准品、质控及待测样本各50ul。
3.每孔加入25ul样本稀释液A。
4.每孔加入25ul样本稀释液B。
5.封板,以300-400rpm速度震荡,室温下过夜(14-18小时)。
6.洗板3次,在吸水纸上拍干。
7.每孔加入50ul抗体-生物素结合物。
8.封板,以500-700rpm速度震荡,室温下孵育1.5小时。
9.洗板6次,在吸水纸上拍干。
10.每孔加入50ul链霉和素-辣根过氧化物酶结合物。
11.封板,以500-700rpm速度震荡,室温下孵育20分钟。
12.洗板6次,洗完最后一次以后,将洗液在孔内停留15分钟再除去。在吸水纸上拍干。
13.在每孔中加入100ulTMB底物溶液。
14.以500-700rpm速度震荡,室温下避光孵育15-30分钟。
15.每孔加入100ul终止液。
16.30分钟内在450nm处读数。
注:必须以零标准作空白。如果能做到双波长测定,可在600或620nm处读数,将600(620)nm吸收值从450nm处减去,这样可以减少光学误差。 使用血清样本,静脉穿刺术采集血液。样本于2-8ºC可保存24小时,-20ºC或以下可保存30天。避免反复冻融样本。不应采用溶血或脂血的样本。冰冻的样本在实验前应解冻,并充分混匀。向左转|向右转
抑制剂刺激细胞后,需要用PBS清洗后再做后续实验吗
ajtr0009-1230.pdf(2384.3k)
我做的是细胞因子的刺激和抑制某条通路后观察是否有影响,分组为空白组,空白+抑制剂,刺激组,刺激+抑制剂,最开始用的单因素方差分析,LSD-T和SNK-Q检验,但是同学说我这里面有两个处理因素,所以不能单因素方差分析,应该直接空白和空白+抑制,空白和刺激,刺激和刺激+抑制剂进行独立样本T检验,现在脑子是混乱的,拜托园子里的大神们帮我看看,感激不尽!!
支原体培养则是取样后在培养基上培养,看有多少支原体菌落会长出,是比较直观和可信的结果。
总体来讲,这两种检查手段可信度都较高,结合一起,不仅可以可靠的知道有无解脲支原体感染,还能知道感染是否严重。
我用conA和LPS分别刺激脾细胞,当然细胞均有明显的增殖,可是如果把这两种有丝分裂原同时用来刺激细胞时,细胞的增殖明显受到了抑制,比起单独采用ConA或者LPS都低很多。conA和LPS分别刺激T细胞和B细胞的增殖,两者同时加入时,作用应该更强,为什么反而大幅减弱呢?
此外,我研究的这种成分单独刺激皮细胞时,细胞也有一定程度的增殖,但是如果这种物质与conA联合使用时,比起单独用conA时,细胞的增殖程度明显降低了一些,这又是什么原因呢?难道可以解释为我研究的这种物质有类似于LPS的作用——刺激B细胞增殖?
如果真的是这样来解释,哪位大侠能把第一个现象(conA和LPS共同作用产生拮抗)的机理帮我解释一下呢?

